Core Insights - Bluefan Medical (002382) reported a closing price of 5.62 yuan on October 27, 2025, with a decrease of 0.35% and a trading volume of 76,700 hands, resulting in a transaction amount of 43.11 million yuan [1] Fund Flow Analysis - On October 27, 2025, the net outflow of main funds was 6.6866 million yuan, accounting for 15.51% of the total transaction amount, while retail investors saw a net inflow of 3.5591 million yuan, representing 8.26% of the total transaction amount [1][2] - Over the past five days, the main funds experienced consistent outflows, with the largest outflow recorded on October 22 at 2.8389 million yuan, while retail investors consistently showed net inflows [2] Company Performance Metrics - Bluefan Medical's total market value is 5.66 billion yuan, significantly lower than the industry average of 11.652 billion yuan, ranking 62 out of 124 in the medical device industry [3] - The company reported a net profit of -135 million yuan, with a year-on-year decline in main revenue of 7.49% to 2.781 billion yuan [3] - The gross profit margin stands at 14.34%, which is considerably lower than the industry average of 51.35%, ranking 120 out of 124 [3] - The company's debt ratio is 41.19%, with financial expenses amounting to 69.4351 million yuan [3]

本 公 告 乃 由 上 海 百 心 安 生 物 技 術 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 情 況 的 最 新 資 料。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不會就本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 Shanghai Bio-heart Biological Technology Co., Ltd. 上海百心安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：2185） 自願公告 IBERIS® RDN系統於瑞士的首個商業案例 承董事會命 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，最 近，本 公 司 附 屬 公 司 上 海 安 通 醫 療 科 技 有 限 公 司（「安 通 ...

Group 1 - The company held its 31st meeting of the 6th Board of Directors on October 21, 2025, via electronic communication, with all 8 directors participating [2][3] - The Board proposed to lower the conversion price of the "Blue Sail Convertible Bond" due to the stock price being below 85% of the conversion price for at least 15 out of the last 30 trading days, which triggers the condition for price adjustment [3][34] - The proposed adjustment will be submitted to the shareholders' meeting for approval, and the new conversion price must not be lower than the higher of the average stock price over the 20 trading days prior to the meeting and the last trading day's price, nor lower than the latest audited net asset value per share and the par value [3][47] Group 2 - The company plans to hold the 5th extraordinary shareholders' meeting of 2025 on November 7, 2025, to discuss the proposed adjustment of the bond conversion price [8][12] - The meeting will be conducted both in-person and via online voting, with specific time slots for voting outlined [13][22] - The record date for shareholders to attend the meeting is October 31, 2025, and all registered shareholders can participate [15][18]

Group 1 - The board of directors of Lanfang proposed to adjust the conversion price of Lanfang Convertible Bonds [1][2] - Wanfu Convertible Bonds will not undergo any adjustment [1][2] - Shareholders of Lihua Micro intend to reduce their holdings by no more than 3% of the company's shares [1] Group 2 - The current price of Jingxing Convertible Bonds is 177.100, with a strong redemption price of 100.290 and a remaining scale of 0.040 billion [4] - Montai Convertible Bonds have a current price of 122.900, a strong redemption price of 101.190, and a remaining scale of 0.800 billion [4] - New 23 Convertible Bonds are priced at 139.625, with a strong redemption price of 100.219 and a remaining scale of 2.259 billion [4] Group 3 - The current price of Pudong Development Bank Convertible Bonds is 110.850, with a redemption price of 110.000 and a remaining scale of 30.947 billion [6] - Tianlu Convertible Bonds are priced at 293.269, with a redemption price of 110.000 and a remaining scale of 0.602 billion [6] - Tongguang Convertible Bonds have a current price of 158.888, with a redemption price of 113.000 and a remaining scale of 0.757 billion [6]

Core Insights - As of October 21, 2025, Bluestar Medical (002382) closed at 5.71 CNY, with a slight increase of 0.53% and a trading volume of 79,400 hands, amounting to a total transaction value of 45.34 million CNY [1] Fund Flow Analysis - On October 21, 2025, the net outflow of main funds was 710,900 CNY, accounting for 1.57% of the total transaction value, while retail investors saw a net inflow of 236,700 CNY, representing 5.22% of the total transaction value [1][2] - Over the past five days, the fund flow data indicates fluctuating trends, with significant net inflows and outflows from both main and retail investors on different days [2] Company Performance Metrics - Bluestar Medical's total market capitalization is 5.751 billion CNY, with a net asset value of 9.905 billion CNY, ranking 62nd in the medical device industry [3] - The company reported a net profit of -135 million CNY for the first half of 2025, which is a 15.88% increase year-on-year, despite a 7.49% decline in main revenue to 2.781 billion CNY [3] - The gross profit margin stands at 14.34%, significantly lower than the industry average of 51.85%, indicating challenges in profitability [3]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 10 月 21 日，蓝帆医疗股份有限公司（以下简称"公司"）股价 已出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价格 85%的情 形，已触发"蓝帆转债"转股价格向下修正条件。 2、经公司第六届董事会第三十一次会议审议通过，公司董事会提议向下修正 "蓝帆转债"转股价格。 | 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于董事会提议向下修正"蓝帆转债"转股价格的公告 3、本次向下修正"蓝帆转债"转股价格的提议尚需提交公司股东会审议。 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 28 日公开发行了3,144.04 万张可转换公司债券（以下简称"可转债"），每张面值100 元，发 行总额314,404 万元。 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于召开2025年第五次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 经蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）第六届董事会第三 十一次会议审议通过，公司决定于 2025 年 11 月 7 日召开 2025 年第五次临时股东会， 现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第五次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：本次召开股东会的议案经公司第六届董事会第三 十一次会议审议通过。本次股东会的召集、召开符合《中华人民共和国公司法》《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《蓝帆医疗股 份有限公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-084 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三十一次会议于 2025 年 10 月 17 日以电子邮件的方式发出通知，于 2025 年 10 月 21 日以通讯表决的方式召 开。本次会议应参加会议董事 8 人，实际参加会议董事 8 人，全体董事以通讯的方式 出席会议。公司董事长刘文静女士主持了本次会议。会议的通知、召开、表决程序符 合《中华人民共和国公司法》和《蓝帆医疗股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议并通过了《关于董事会提议向下修正"蓝帆转债"转股价格的议案》； 截至2025年10月21日，公司股票已出现连续三十个交易日中至少有十五个交易日 的收盘价低于当期转股价格85%的情形，已触发"蓝帆转债"转股价格向下修正条件。 为充分保护债券持有人利益，优化公司资本结构，支持公司长期发展，董事会提 议向下修正"蓝帆转债"转股价格，该提议尚需提交公司股东会审议。修正后的转股 ...

Core Viewpoint - Bluefan Medical (002382) has shown a mixed performance in recent trading, with a slight increase in stock price but a significant decline in financial metrics, indicating potential challenges ahead for the company [1][3]. Financial Performance - As of October 20, 2025, Bluefan Medical's stock closed at 5.68 yuan, up 3.27% with a trading volume of 156,500 shares and a total transaction value of 88.86 million yuan [1]. - The company reported a main operating revenue of 2.781 billion yuan for the first half of 2025, a year-on-year decrease of 7.49% [3]. - The net profit attributable to shareholders was -135 million yuan, which represents a year-on-year increase of 15.88% [3]. - The second quarter of 2025 saw a significant decline in performance, with a single-quarter main operating revenue of 1.303 billion yuan, down 16.0% year-on-year, and a net profit of -212 million yuan, a decrease of 245.53% [3]. Market Position and Ratios - Bluefan Medical's total market capitalization is 5.721 billion yuan, ranking 62nd in the medical device industry, which has an average market cap of 11.662 billion yuan [3]. - The company has a price-to-earnings ratio (P/E) of -21.22, compared to the industry average of 65.67, indicating a challenging earnings environment [3]. - The company's price-to-book ratio (P/B) stands at 0.73, significantly lower than the industry average of 3.77, suggesting undervaluation relative to its book value [3]. - Bluefan Medical's gross margin is 14.34%, which is considerably lower than the industry average of 51.83%, reflecting operational inefficiencies [3]. Capital Flow Analysis - On October 20, 2025, the net inflow of main funds was 9.7742 million yuan, accounting for 11.0% of the total transaction value, while retail investors saw a net outflow of 14.9712 million yuan, representing 16.85% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net inflows and outflows from both institutional and retail investors [2].

Core Viewpoint - The article highlights the rapid growth and strategic transformation of Runxinwei, a company founded by Liu Qing, from a software service provider to a comprehensive soft and hardware provider in the automotive and smart device sectors, achieving over 50% annual revenue growth and securing significant partnerships with major automotive manufacturers [4][5]. Company Transformation - Liu Qing founded Runxinwei in 2020 after leaving her position as a vice president at a listed company, aiming to expand beyond mobile operating systems into the automotive sector, particularly focusing on smart cockpits [4][8]. - The company launched the SailingCore operating system, which integrates various smart devices into a cohesive ecosystem, achieving over one million units shipped in smart cockpit products [5][15]. Product Development and Market Strategy - Runxinwei's smart cockpit products, such as C100 and C200, are designed to connect with various devices, providing a seamless user experience across different environments [12][13]. - The company targets the mid-to-low-end vehicle market to demonstrate its technological capabilities, with products priced around 50,000 yuan, making smart features accessible to a broader audience [12][21]. Technological Innovation - The SailingCore operating system enables real-time data synchronization between devices, breaking down information silos and enhancing user experience [15][19]. - Runxinwei has invested significantly in R&D, with over 90% of its workforce dedicated to this area, resulting in more than 160 patents and software copyrights [15][19]. Business Segments - The company operates in four main business segments: smart automotive, mobile devices, robotics, and smart home solutions, with the automotive segment showing the most rapid growth [21]. - Runxinwei has established partnerships with major automotive manufacturers, including SAIC, GAC, and Dongfeng, securing substantial orders [5][21]. Company Culture and Management - Runxinwei emphasizes a flat management structure, fostering innovation and quick decision-making, while also implementing a unique incentive system to maintain employee engagement [24][25]. - The company adopts a "fast and slow" approach in operations, balancing rapid product development with a commitment to foundational research [26][27]. Market Expansion - Runxinwei is actively expanding its market presence internationally, with offices established in Europe, North America, the Middle East, and South America [27]. - The company focuses on nurturing existing client relationships while exploring new opportunities in overseas markets [27][28].